Clinical Trial

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality bladder conservative approach.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-12-02; most recent amendment 2022-10-25.
Status change: Recruiting → Active, Not Recruiting 2022-10-25
Trial Details
NCT Number NCT04186013
Lead Sponsor Spanish Oncology Genito-Urinary Group
Collaborators: Roche Farma, S.A, Dynamic Science S.L.
Conditions Bladder Cancer
Enrollment 39 participants
Start Date 2019-09-18
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2022-10-26